IGM BIOSCIENCES, INC. (IGMS): Price and Financial Metrics

IGM BIOSCIENCES, INC. (IGMS): $7.28

0.66 (-8.31%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add IGMS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#284 of 351

in industry

IGMS Price/Volume Stats

Current price $7.28 52-week high $17.70
Prev. close $7.94 52-week low $3.81
Day low $7.20 Volume 196,900
Day high $8.24 Avg. volume 312,268
50-day MA $8.80 Dividend yield N/A
200-day MA $8.56 Market Cap 429.69M

IGMS Stock Price Chart Interactive Chart >


IGM BIOSCIENCES, INC. (IGMS) Company Bio


IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The company was founded in 2010 and is headquartered in Mountain View, CA.


IGMS Latest News Stream


Event/Time News Detail
Loading, please wait...

IGMS Latest Social Stream


Loading social stream, please wait...

View Full IGMS Social Stream

Latest IGMS News From Around the Web

Below are the latest news stories about IGM BIOSCIENCES INC that investors may wish to consider to help them evaluate IGMS as an investment opportunity.

15 Best Falling Stocks To Buy Now

In this piece, we will take a look at the 15 best falling stocks to buy now. If you want to skip our overview of the current stock market environment and our coverage of the latest stock market news, then you can skip ahead to 5 Best Falling Stocks To Buy Now. With 2023 coming […]

Yahoo | December 8, 2023

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease – – All clinical development in hematologic oncology indications halted – – Cash runway expected to extend into second quarter 2026 – – Reduction in workforce of approximately 22 percent – MOUNTAIN VIEW, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnol

Yahoo | December 5, 2023

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Today on 1 December 2023, Medivir AB (publ) (the "Company") held an extraordinary general meeting in Stockholm, whereby the resolution below was adopted. The general meeting was held at Helio GT30 on Grev Turegatan 30 in Stockholm. For more detailed information on the content of the resolution, please see the complete notice of the extraordinary general meeting that is available on the Company's website, www.medivir.com. Minutes from the extraordinary general meeting will be provided on the said

Yahoo | December 1, 2023

Medivir to present at the Erik Penser Bank Company Event

Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Erik Penser Bank Company Event on Thursday, November 23, at 10.10 CET.

Yahoo | November 21, 2023

We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | November 19, 2023

Read More 'IGMS' Stories Here

IGMS Price Returns

1-mo -21.04%
3-mo -26.61%
6-mo -7.38%
1-year -24.64%
3-year -91.34%
5-year N/A
YTD -12.39%
2023 -51.15%
2022 -42.00%
2021 -66.78%
2020 131.37%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!